Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disease involving the integumental system.
No HPO annotations are available for this condition.
Age of onset: at birth, before birth.
GJB2-related autosomal recessive nonsyndromic hearing loss (GJB2-AR NSHL) is the most common genetic cause of congenital (present at birth) severe-to-profound non-progressive sensorineural hearing loss in many world populations. GJB2-AR NSHL can also be mild to moderate and is usually not progressive; however, there are exceptions. Severe-to-profound GJB2-AR NSHL is typically congenital and diagnosed on newborn hearing screening (NBHS); however, there are occasional exceptions. In two examples, a newborn passed his NBHS auditory brain stem response (ABR)-based test, but was diagnosed as deaf at age 15 months when an ABR test obtained at the request of his parents showed no responses through 90 dB.
The diagnosis of GJB2-related autosomal recessive nonsyndromic hearing loss (GJB2-AR NSHL) should be considered in two scenarios: an and a .
Universal NBHS using physiologic screening (either otoacoustic emissions [OAE], which measure the response of cochlear outer hair cells to auditory stimuli, or automated auditory brain stem response [ABR], which measures the physiologic response of cochlear inner hair cells, auditory nerve, brain stem, and brain to auditory stimuli) is required by law or rule in all 50 states in the United States and is performed on 98% of children in the US typically within days after birth (see 2020 Summary of National CDC EHDI Data).
No approved treatments are currently available for integumentary system disorder. The disease remains an area of unmet medical need.
No clinical practice guidelines specific to GJB2-related autosomal recessive nonsyndromic hearing loss (GJB2-AR NSHL) have been published. Management ideally occurs in the context of a multidisciplinary clinic with specialists in otolaryngology, audiology, and genetic counseling. See Genetic Hearing Loss Overview, Management.
To establish the extent of involvement and needs in an individual diagnosed with GJB2-AR NSHL, the following evaluations by an otolaryngologist are recommended:
To monitor the individual's response to habituation and to identify any changes in severity of hearing loss, the following evaluations are recommended. Most children with severe-to-profound GJB2-AR NSHL with a cochlear implant will initially have frequent evaluations recommended by their cochlear implant team (otolaryngologist, audiologist, and speech and language pathologist). At follow-up appointments, the following may be performed: speech recognition testing, equipment checks (including device adjustment and troubleshooting), and provision of replacement or upgraded equipment . As the cochlear implant recipient becomes comfortable with the cochlear implant, many of the above tasks can be performed by the family at home, obviating the need for routinely scheduled appointments unless the need for a clinic visit arises.
No clinical trials have been registered for integumentary system disorder.
317 publications have been identified in PubMed for integumentary system disorder. Kisho has analyzed 181 by research type. Research spans Review / Meta-Analysis (54%), Basic Science / Preclinical (32%), and Epidemiology / Natural History (7%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 97 | 54% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:49 PM UTC
Source: GeneReviews — "GJB2-Related Autosomal Recessive Nonsyndromic Hearing Loss"
Source: GeneReviews — "GJB2-Related Autosomal Recessive Nonsyndromic Hearing Loss"
As of this writing, more than 70 genes have been associated with autosomal recessive nonsyndromic hearing loss. For a list of selected genes associated with distinctive clinical features, see Genetic Hearing Loss Overview, Table 3. For a current, comprehensive list of all identified autosomal recessive nonsyndromic hearing loss genes, see Hereditary Hearing Loss Homepage.
Source: GeneReviews — "GJB2-Related Autosomal Recessive Nonsyndromic Hearing Loss"
Biomarker and diagnostic research for integumentary system disorder has been reported in the published literature.
Source: GeneReviews — "GJB2-Related Autosomal Recessive Nonsyndromic Hearing Loss"
Individuals with hearing loss should avoid environmental exposures known to cause hearing loss. Most important for persons with GJB2-related mild-to-moderate hearing loss is avoidance of repeated overexposure to loud noises, particularly secondary to earbud use. The headphone safety feature built into most smartphones can be set a maximum limit of 75 dB. Headphone/earbud safety features can be found in the phone settings menu:
In iPhones, under Settings Sounds Haptics Headphone Safety
In Android phones, under Settings Sounds Vibrations Volume Media volume limit
Also see these general resources on noise reduction:
• 6 Simple Ways To Check If Your Headphones Are Too Loud
• How Do I Prevent Hearing Loss from Loud Noise?
Source: GeneReviews — "GJB2-Related Autosomal Recessive Nonsyndromic Hearing Loss"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this condition.
Source: GeneReviews — "GJB2-Related Autosomal Recessive Nonsyndromic Hearing Loss"
View trials for integumentary system disorder
Children with mild-to-moderate GJB2-AR NSHL
Source: GeneReviews — "GJB2-Related Autosomal Recessive Nonsyndromic Hearing Loss"
Laboratory research |
58 |
32% |
Disease patterns and progression | 12 | 7% |
Clinical study results | 5 | 3% |
Testing and diagnosis research | 4 | 2% |
Patient case studies | 3 | 2% |
New treatment approaches | 2 | 1% |
Guo Z (2026). [PMID: 41836406](https://pubmed.ncbi.nlm.nih.gov/41836406/). *Front Immunol*. [Review / Meta-Analysis]
Rech KL (2026). [PMID: 41651609](https://pubmed.ncbi.nlm.nih.gov/41651609/). *Surgical pathology clinics*. [Review / Meta-Analysis]
Liu M (2026). [PMID: 41105632](https://pubmed.ncbi.nlm.nih.gov/41105632/). *Brain*. [Basic Science / Preclinical]
Yu S (2026). [PMID: 41448402](https://pubmed.ncbi.nlm.nih.gov/41448402/). *The Journal of allergy and clinical immunology*. [Basic Science / Preclinical]
Alenezi S (2026). [PMID: 39824360](https://pubmed.ncbi.nlm.nih.gov/39824360/). *Journal of the American Academy of Dermatology*. [Review / Meta-Analysis]
Inoue S (2026). [PMID: 41327822](https://pubmed.ncbi.nlm.nih.gov/41327822/). *J Dermatol*. [Review / Meta-Analysis]
Seki T (2026). [PMID: 41665963](https://pubmed.ncbi.nlm.nih.gov/41665963/). *JCI Insight*. [Basic Science / Preclinical]
Moore L (2026). [PMID: 41965049](https://pubmed.ncbi.nlm.nih.gov/41965049/). *Rev Med Virol*. [Review / Meta-Analysis]
Sun J (2026). [PMID: 40829507](https://pubmed.ncbi.nlm.nih.gov/40829507/). *Biomaterials*. [Basic Science / Preclinical]
Grant JE (2026). [PMID: 41252799](https://pubmed.ncbi.nlm.nih.gov/41252799/). *Comprehensive psychiatry*. [Epidemiology / Natural History]